Gastric cancer

Researchers are testing whether a combination of two immunotherapy drugs, tremelimumab and durvalumab, can treat MSI-high gastric or gastroesophageal junction cancer without immediate surgery. The trial enrolls adults with resectable tumors and gives the drugs before a planned op…

This phase 2 trial is testing whether a therapeutic cancer vaccine called AST-301 can safely train the immune system to fight HER2-expressing gastric cancer cells. The study enrolls people with stage II or III gastric cancer who have already had surgery and completed standard adj…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This pilot study tests whether giving a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation therapy before surgery can help treat stomach cancer that can be surgically removed. The study includes 32 participants and primarily lo…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This phase III trial is testing whether adding radiotherapy to standard chemotherapy improves survival in patients with HER2 negative esophageal or gastric cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemot…

This study tests whether giving immunotherapy before surgery can help people with MSI/dMMR tumors. The goal is to shrink or eliminate the tumor before it is removed, potentially improving survival. The trial includes adults with localized, resectable cancers such as colorectal, g…

This phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard chemotherapy before surgery helps patients with advanced stomach or gastroesophageal junction cancer. About 116 participants will receive either the combo or chemo alone for three cycles before…

Researchers are testing whether combining FLOT chemotherapy, trastuzumab and toripalimab before and after surgery helps people with HER2-positive stomach or esophagogastric junction cancer. The trial enrolls about 30 adults with locally advanced, operable tumors. Participants rec…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-stage trial tests an experimental drug called ONO-4578, both on its own and together with another experimental drug, ONO-4538, in people with advanced or metastatic solid tumors. The study also includes separate groups for people with gastric cancer or colorectal cance…

This phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab first, followed by a combination of ramucirumab and paclitaxel, can shrink tumors and delay progression in people with advanced gastric or gastroesophageal junction adenocarcinoma. The study enrolls…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This study tests a drug called zolbetuximab that targets a protein (CLDN18.2) found in many stomach and gastroesophageal junction tumors. The drug is given alone or with chemotherapy and/or immunotherapy to see how well it controls tumor growth. The study includes 143 adults with…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This early-stage trial tests an experimental drug called DM001 in people with advanced solid tumors, including breast cancer, non-small cell lung cancer, and other solid cancers that have progressed on standard treatment. The main goals are to find a safe dose, identify side effe…

This study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by s…

This trial tests a new drug called BAY 1895344 (elimusertib) combined with standard chemotherapy (FOLFIRI) in people with advanced or metastatic stomach or colorectal cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants receive th…

This study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will track how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, including …

This study looks at whether a combination of two immunotherapy drugs (Durvalumab and Tremelimumab) can control advanced stomach cancers with specific genetic features (dMMR/MSI-H) well enough to avoid surgery. The trial enrolls 12 adults who would normally need chemotherapy and s…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This trial is testing whether giving a PD-1 immunotherapy drug after surgery can help people with a specific type of stomach cancer (MSI-H) live longer without the cancer coming back. Participants who had surgery to remove their stomach cancer will be randomly assigned to receive…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This phase 2 trial is testing whether adding surufatinib (a targeted therapy that blocks blood vessel growth) to standard immunotherapy and chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment is given befor…

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This phase 2 trial tested a combination of two drugs, berzosertib and irinotecan, in 17 patients with advanced stomach or gastroesophageal junction cancer that has a specific genetic change (TP53 mutation) and was getting worse. The goal was to see if the combination could shrink…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This early-phase trial is testing whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and lenvatinib (which blocks enzymes that help tumors grow)—can shrink tumors in people with advanced stomach or gastroesophageal cancer that …

This early-phase trial tests whether a shorter course (2 weeks instead of 5) of chemoradiotherapy before standard chemotherapy and surgery is safe and effective for people with resectable stomach cancer. About 25 participants will receive the shortened radiation combined with che…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…

This study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…

This Phase 3 trial tests a new drug called AZD0901 against standard chemotherapy in 592 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The study me…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…

This early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive th…

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This Phase 3 trial tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 626 participants who have not had prior chemotherapy will re…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, an…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…

This study explores whether a blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide if patients with stage II-III gastric cancer need chemotherapy after surgery. About 65 patients will be followed for three years to see if those with no detectable ctDNA c…

This phase 2 trial is testing a five-drug combination for people with advanced esophageal, stomach, or gastroesophageal junction cancer that has worsened after initial treatment. The combination includes immune cells from healthy donors, two immunotherapy drugs, and two standard …

This study looks at whether surgery to remove stomach cancer that has spread to the abdomen can help people live longer when done after chemotherapy. About 300 adults whose cancer responded well to initial treatment will be randomly assigned to either have surgery plus more thera…

This study tests a new device called the Luso-Cor esophageal stent for closing leaks (fistulas) that can happen after weight-loss or cancer surgery on the stomach or esophagus. About 180 adults will be enrolled and their outcomes compared to those treated with standard stents or …

This study is testing whether a newer, less invasive type of stomach cancer surgery (using just one or a few small cuts) is as safe and effective as the standard approach. The trial involves 108 people with advanced stomach cancer who need their stomach partially removed. The mai…

This study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the …

This early-phase study is testing whether a diet low in the amino acid leucine, given for just three days before surgery, is safe for people with stomach cancer. Researchers will check blood amino acid levels, immune cell changes, and any side effects. The goal is to see if this …

This early-phase trial tests a new drug called IDX-1197 combined with standard chemotherapy (XELOX or irinotecan) in 87 people with advanced stomach cancer. The main goal is to find the safest dose and check for side effects. It is not yet known if the combination works better th…

This early-phase trial is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study involves 27 pa…

This phase 2 trial tests whether a combination of lenvatinib, pembrolizumab, and chemotherapy (FLOT) can shrink stomach tumors before surgery and prevent recurrence afterward. It involves 43 adults with untreated, non-metastatic stomach cancer. The main goal is to see how many pa…

This study tests a procedure called PIPAC, which turns chemotherapy drugs into a mist and sprays them directly into the abdomen. It is for people with stomach cancer that has spread to the lining of the belly. The goal is to see if this approach is safe and can help control the d…

This study tests a new antibody drug, S095029, combined with the immunotherapy pembrolizumab in people with advanced stomach or gastro-esophageal junction cancer that has a specific genetic feature (MSI-H/dMMR). The trial aims to see if the combination is safe and can shrink tumo…

This pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increa…

This study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemorad…

This early-stage study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have come back or spread and no longer respond to standard treatments. The main goal is to check the drug's safety and find the…

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This phase 2 trial tests whether adding an experimental drug (ONO-4578) to standard immunotherapy (nivolumab) and chemotherapy helps people with advanced HER2-negative stomach cancer. About 226 participants who have not had prior chemotherapy will receive either the experimental …

This phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the v…

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…

This study tests a new genetic vaccine called Nous-209, given together with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced MSI-H or dMMR solid tumors (colorectal, gastric, or gastro-esophageal junction cancers). The vaccine is designed to train the immun…

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …

This phase II trial tests a combination of chemotherapy drugs for stomach cancer that has spread to the lining of the abdomen. About 40 adults will receive standard intravenous chemo plus paclitaxel infused directly into the abdomen. The goal is to see if this approach improves h…

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This early-stage trial tests whether adding two drugs—pucotenlimab (an immunotherapy) and lenvatinib (a targeted therapy)—to standard chemotherapy (SOX) can shrink tumors better than chemotherapy alone in people with advanced HER2-negative stomach or gastroesophageal junction can…

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab before standard chemotherapy and radiation can help prevent stomach cancer from coming back. It includes 40 people with operable stomach cancer that has either a specific DNA repair problem (mismat…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard FLOT chemotherapy can improve outcomes for people with stage III gastric cancer. About 138 participants will receive either the combo or chemo alone before surgery. The main goal is to see if t…

This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…

This early-stage trial is testing a new drug called ELVN-002 in combination with trastuzumab and chemotherapy for people with advanced HER2-positive solid tumors, including breast, gastric, and colorectal cancers. The main goal is to find a safe dose and understand side effects. …

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or slow disease progres…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug …

This phase II trial tests a combination of three drugs—fruquintinib, sintilimab, and SOX (S-1 plus oxaliplatin)—as a pre-surgery treatment for people with stage IV gastric cancer that cannot be fully removed. The goal is to shrink the tumor enough to allow complete surgical remov…

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…

This study tests a new drug (RC48-ADC) combined with immunotherapy (toripalimab) and either chemotherapy or another targeted drug (trastuzumab) as a first treatment for people with advanced stomach cancer. About 201 adults aged 18-75 with HER2-positive or HER2-negative stomach ca…

This early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal ju…

This study tests an experimental drug called ASKB589 in about 199 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. People with stomach or pancreatic cancer are especially wanted for …

Researchers test whether flushing the biopsy needle with heparin, a blood thinner, helps collect more and better tissue from solid abdominal tumors during endoscopic ultrasound-guided fine needle biopsy. They also test whether using a microsieve to prepare the tissue improves the…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This study tests whether two imaging tools—laser speckle contrast imaging (LSCI) and digital thermography—can objectively grade mesenteric traction syndrome (MTS), a frequent complication during abdominal surgery that causes low blood pressure, rapid heart rate, and facial flushi…

This study looks at whether a special type of CT scan (spectral CT) combined with a tumor marker (MSI status) can more accurately predict if stomach cancer has spread to nearby lymph nodes. Researchers will compare the CT results with the actual lymph node findings after surgery …

This study tests a new magnetic tracer, FerroTrace, to find sentinel lymph nodes in people with stomach or esophageal cancer. About 60 participants will receive the tracer before standard treatment, and doctors will compare its accuracy to current methods. The goal is to see if t…

This study looks at whether testing stool (feces) for certain DNA changes and bacteria genes can help find stomach cancer early. Researchers will follow 3000 people, including those with and without cancer, to see how well the test works. The goal is to improve early diagnosis an…

This study tests whether curcumin, a compound found in turmeric, can prevent stomach cancer in people with chronic atrophic gastritis or gastric intestinal metaplasia. About 50 participants will receive either curcumin or a placebo for a period, and researchers will measure chang…

Researchers are testing an experimental vaccine called Ad5.F35-hGCC-PADRE in adults who have had surgery and standard treatment for gastrointestinal cancers, including pancreatic, colorectal, esophageal, gastric, and small bowel adenocarcinomas. The trial aims to find a safe dose…

This study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal junction cancer from returning in the abdominal lining. The treatment uses drugs cisplatin and paclitaxel, which are heated and circulated in the b…

This study screens 500 adults in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and gastric cancer. Those who test positive receive free treatment with a three-drug combination (VOQUEZNA® Triple Pak®) for 14 days. The goal is to see i…

This study screens people in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and even stomach cancer. Those who test positive receive treatment, and the study compares at-home breath testing versus in-person retesting to confirm the in…

This study tests whether personalized screening can prevent stomach and colon cancer in 40,000 healthy adults aged 50-75. For stomach cancer, researchers combine a test for H. pylori bacteria with a blood test for stomach damage to identify high-risk individuals. For colon cancer…

This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…

This Phase 3 trial tests a drug called M701, given as an injection into the belly, to see if it can reduce the need for draining fluid in people with malignant ascites from advanced stomach, colorectal, or ovarian cancer. About 312 participants will either receive M701 plus drain…

This study tests a telehealth program designed to help people improve their diet and quality of life after surgery for stomach or esophagus cancer. About 53 patients who have had curative surgery will receive virtual sessions with diet support. The goal is to see if the program i…

This trial tests whether a combination of acetaminophen and ibuprofen (Maxigesic) given through an IV can control pain better than acetaminophen alone after laparoscopic or robotic stomach cancer surgery. About 90 adults undergoing this surgery will be randomly assigned to one of…

This study compares two minimally invasive surgeries for cancer at the top of the stomach or where the stomach meets the esophagus: removing only the upper part (proximal gastrectomy) versus removing the entire stomach (total gastrectomy). The goal is to see which approach leads …

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study tests whether a personalized care plan, based on a geriatric assessment, can reduce severe side effects in older adults (65+) starting chemotherapy for common cancers. Participants are randomly assigned to receive the assessment-driven plan plus usual care, or usual ca…

This study looks at whether a structured care plan right after surgery can improve quality of life and recovery for people with gastric cancer who had chemotherapy or radiation before surgery. About 264 adults aged 18-80 will take part. The goal is to see if this approach reduces…

This trial compares two surgeries—removing part of the stomach (resection) versus creating a bypass—to relieve blockages in advanced stomach cancer. It includes 63 patients with obstructed tumors. The main goal is to see which procedure better eases symptoms like nausea and vomit…

This phase II trial tests an enhanced recovery after surgery (ERAS) protocol in 52 people with stage 0 to IIIC gastric cancer who are having surgery. The goal is to see if this approach can reduce pain, nausea, and hospital stays while improving quality of life. Participants rece…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, …

This study looks at how a specific gene change (called hMLH1 hypermethylation) affects stomach cancer. Researchers will study 245 patients who had stomach cancer surgery to find links between lifestyle, genetics, and how the cancer behaves. The goal is to better understand why so…

This study examines the extra costs of doing an upper endoscopy (stomach scope) at the same time as a routine colonoscopy for colon cancer screening. Researchers will also analyze the overall economic burden of treating stomach cancer. Data from 250 patients will be collected fro…

This study explores whether artificial intelligence can predict if stomach cancer will come back within a year after surgery. Researchers will analyze CT scans and clinical data from 900 patients with locally advanced gastric cancer. The goal is to build a model that helps doctor…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study looks at 80 patients with both locally advanced gastric cancer and high blood pressure. Researchers want to see if taking beta-blockers (a common blood pressure drug) alongside standard cancer treatment leads to better tumor shrinkage compared to other blood pressure d…

This study looks at genetic changes in people with H. pylori infection or stomach cancer to understand how the infection can lead to cancer. Researchers will analyze tissue samples from 110 adults undergoing endoscopy. The goal is to find early warning signs and possible ways to …

This study looks at how anemia changes blood flow in the smallest blood vessels (microcirculation) in patients having open surgery for gastric cancer. Researchers will compare 27 anemic patients with 27 non-anemic patients, all receiving standard goal-directed fluid therapy. They…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study follows 197 people with stage II-III gastric cancer who had surgery. Researchers want to see if using a blood test (ctDNA) to guide post-surgery treatment works as well as standard chemotherapy. The goal is to learn if some patients can safely receive less intense trea…

This study looks at whether using a small camera (laparoscopy) to see if stomach cancer has spread inside the belly can help doctors choose the best treatment. About 968 people with stage III stomach cancer will be randomly assigned to either standard care or care guided by this …

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study is testing whether an artificial intelligence model can predict duodenal stump leakage, a serious complication that can occur after laparoscopic surgery to remove stomach cancer. The research involves 1200 participants who have had or will have this surgery. The goal i…

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This study explores whether 3D bioprinting can create personalized models of liver cancer from a patient's own tumor tissue. Researchers will test different drugs on these models to see which ones work best, aiming to predict a patient's response before treatment. The goal is to …

This study looks at how a patient's age influences the type of treatment they receive for stomach cancer that can be removed with surgery, and how that affects their survival. Researchers will analyze genetic information from tumors to better understand why age matters. The goal …

This study tests whether an artificial intelligence (AI) model can help pathologists diagnose gastric cancer more accurately and quickly. About 1000 patients with gastric biopsies or surgical samples will take part. Some pathologists will use the AI tool to assist their diagnosis…

This study looks at whether leaving a breathing tube in for 24-48 hours after gastric cancer surgery can lower complications in patients who also have severe obstructive sleep apnea. Researchers will compare two groups of 240 patients: one with standard tube removal and one with …

This study looks back at 193 people with stomach, appendix, or colon cancer who had surgery with or without heated chemotherapy (HIPEC). Researchers want to see if HIPEC affects how quickly the bowels start working again after surgery and whether it leads to more complications. T…

This study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …

This study follows 438 older adults (60+) who had surgery for gastric cancer. Researchers want to understand how diet changes over time and how those changes relate to frailty. Participants complete surveys at discharge and at 1, 3, and 6 months after surgery. The goal is to desi…